Viewing Study NCT02644967


Ignite Creation Date: 2025-12-25 @ 12:56 AM
Ignite Modification Date: 2026-01-04 @ 4:29 PM
Study NCT ID: NCT02644967
Status: COMPLETED
Last Update Posted: 2022-08-03
First Post: 2015-12-23
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
Sponsor: Idera Pharmaceuticals, Inc.
Organization: